// App-Quantinova.ai

382.0 : Efficacy and tolerability of sorafenib in unresectable/advanced hepatocellular carcinoma patients: Real-life experience in a Hong Kong tertiary liver cancer institute.

Researchers

Presenter

  • Thomas Cheung Yau

Principal Investigators

  • Vikki Tang

  • Roland Ching-Yu Leung

  • Gin Wai Kwok

  • Joanne Wing-Yan Chiu

  • Tan To Cheung

Medical Centers

  • Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong

  • Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong

  • Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong

Locations

  • Hong Kong

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Sorafenib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved